NuCana PLC (NCNA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.88M
Last updated: Nov 17, 2026 at 11:05 AM ET
NuCana PLC (NCNA) Competitors
The companies most similar to NuCana are CNS Pharmaceuticals (CNSP), Can Fite Biopharma Ltd ADR (CANF) and Imunon (IMNN). By market cap, NuCana ranks 9th of the 13 companies on this page; Enveric Biosciences (ENVB) is the largest at $6.78M.
Peer Comparison
NCNA's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| NuCana (NCNA) | $3.88M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| CNS Pharmaceuticals Inc (CNSP) | $4.22M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Can Fite Biopharma Ltd ADR (CANF) | $4.30M | N/A | 14.3x | 0.0% | -156.8% | 0.0% | 0.00% |
| Imunon Inc (IMNN) | $4.08M | N/A | N/A | 0.0% | -131.5% | 0.0% | 0.00% |
| Curis Inc (CRIS) | $2.97M | N/A | 1.6x | 0.0% | N/A | -66.0% | 0.00% |
| Enveric Biosciences Inc (ENVB) | $6.78M | N/A | 0.2x | 0.0% | N/A | -7.3% | 0.00% |
| Neurosense Therapeutics Ltd (NRSN) | $3.21M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN) | $4.02M | N/A | N/A | 0.0% | -247.2% | 0.0% | 0.00% |
| PharmaCyte Biotech Inc (PMCB) | $3.77M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Traws Pharma Inc (TRAW) | $3.86M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Skye Bioscience, Inc. Common Stock (SKYE) | $4.83M | N/A | N/A | 0.0% | -3685.3% | 0.0% | 0.00% |
| Processa Pharmaceuticals Inc (PCSA) | $5.20M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Lantern Pharma Inc (LTRN) | $6.47M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $4.15M | N/A | 1.6x | 0.0% | -202.0% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to NuCana, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| CNS Pharmaceuticals Inc (CNSP) | CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, is dedicated to the development of cancer drug candidates for the treatment of brain and central... | CNSP competitors |
| Can Fite Biopharma Ltd ADR (CANF) | Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutics for the treatment of cancer... | |
| Imunon Inc (IMNN) | Imunon Inc. is a clinical-stage biotechnology company at the forefront of developing innovative immune-mediated therapies targeting cancer and infectious... | IMNN competitors |
| Curis Inc (CRIS) | Curis, Inc., a biotechnology company, is dedicated to the discovery and development of drug candidates for the treatment of human cancers in the United States. | CRIS competitors |
| Enveric Biosciences Inc (ENVB) | Enveric Biosciences, Inc., a pharmaceutical company, is dedicated to developing various cannabinoid drugs for the treatment of cancer. | ENVB competitors |
| Neurosense Therapeutics Ltd (NRSN) | Neurosense Therapeutics Ltd (NRSN) is a clinical-stage biotechnology firm dedicated to innovating treatments for neurodegenerative diseases... | |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN) | Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is headquartered in LA Palma, California. | LIMN competitors |
| PharmaCyte Biotech Inc (PMCB) | PharmaCyte Biotech, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cell therapies for cancer and diabetes in the United... | PMCB competitors |
| Traws Pharma Inc (TRAW) | Traws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. | TRAW competitors |
| Skye Bioscience, Inc. Common Stock (SKYE) | Skye Bioscience, Inc., a clinical stage biopharmaceutical company, discovers, develops... | SKYE competitors |
| Processa Pharmaceuticals Inc (PCSA) | Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of patients... | PCSA competitors |
| Lantern Pharma Inc (LTRN) | Lantern Pharma Inc., a clinical-stage biotechnology company, focuses on developing precision cancer therapies using artificial intelligence, genomics... | LTRN competitors |
Frequently Asked Questions About NCNA
Who are NuCana's main competitors?
The companies most similar to NuCana include CNS Pharmaceuticals (CNSP), Can Fite Biopharma Ltd ADR (CANF), Imunon (IMNN), Curis (CRIS) and Enveric Biosciences (ENVB), listed from the closest match.
Who is NuCana's biggest competitor?
Enveric Biosciences (ENVB) is the largest of the similar companies at $6.78M; CNS Pharmaceuticals (CNSP) is the closest match by business profile, size, sector and industry.
How does NCNA stock compare with its competitors?
NCNA's net margin is 0.0% against a peer median of 0.0%.
Which of NuCana's competitors pays a higher dividend?
NuCana pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is NuCana bigger than its competitors?
No. NuCana is 9th by market cap among the 13 companies on this page; the largest is Enveric Biosciences (ENVB) at $6.78M.
NCNA pages: Overview, Financials, Competitors